Copyright Nasdaq. Minimum 15 minutes delayed.

Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Dicerna to Present at the Cowen and Company 38th Annual Health Care Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will present at the Cowen and Company...
View HTML
Toggle Summary Dicerna to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on March 8, 2018
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its fourth quarter and full year 2017 financial results after market close on...
View HTML
Toggle Summary Dicerna to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will participate in two investor...
View HTML
Toggle Summary Dicerna to Present at Noble Capital Markets' NobleCon14
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will present at NobleCon14 - Noble...
View HTML
Toggle Summary Dicerna Announces Pricing of Follow-On Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) ("Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced today the pricing of its underwritten registered public offering of 5,714,286 shares of its common stock...
View HTML
Toggle Summary Dicerna Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc . (NASDAQ:DRNA) ("Dicerna" or the "Company"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced today the commencement of a proposed underwritten public offering of shares of its...
View HTML
Toggle Summary Dicerna Announces First Human Dosed in Phase 1 Clinical Trial of DCR-PHXC for Treatment of All Forms of Primary Hyperoxaluria
Clinical Proof-of-Concept Data for First GalXC™ RNAi Product Candidate Expected in Second Half of 2018 CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc . (NASDAQ:DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced the dosing of the first human in...
View HTML
Toggle Summary Dicerna to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will present at the inaugural...
View HTML
Toggle Summary Dicerna to Present at the Stifel 2017 Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough , Ph.D., president and chief executive officer, will present at the Stifel 2017...
View HTML
Toggle Summary Dicerna Reports Third Quarter 2017 Financial and Operating Results and Provides Corporate Update
Management to Host Conference Call Today at 4:30 p.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the third quarter...
View HTML